I'm not sure I'd be investing in "safer, more targeted options for non-invasive external beam radiation therapy". I think that the days for external beam radiation are numbered and rightly so. No such thing as non-invasive EB radiation in my opinion.
You're right about the multinationals though.
My hope is that the Oncosil Board is pushing for a deal with the companies that wanna be huge multinationals by taking over the traditional EB radiation space. Regardless of CE mark. Sure, CE Mark will help a transaction price, but a large company might just go straight to RCT in the US.
Ann: Positive Overall Survival data released at ASCO 2019 Chicago, page-29
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.160(15.7%) |
Mkt cap ! $16.49M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.18 | $1.03 | $51.49K | 47.06K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1817 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 830 | 1 |
View Market Depth
| Last trade - 15.27pm 26/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |